文献速递临床试验与 GCP流行病学与生物统计

口服胶囊与结肠镜输送粪菌移植对复发性艰难梭菌感染的疗效:随机临床试验

Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

在加拿大3个学术中心开展的开放标签非劣效随机试验纳入116例复发性艰难梭菌感染成人患者,比较口服胶囊与结肠镜输送粪菌移植的疗效。符合方案分析显示,单次治疗后12周无复发率两组均为96.2%(差异0%;单侧95%CI -6.1%至无穷;P<.001),达到非劣效界值15%。胶囊组报告体验为「完全不难受」的比例显著更高(66% vs 44%;差异22%[95%CI 3%-40%];P=.01)。

要点

  • 口服胶囊粪菌移植在预防复发性艰难梭菌感染12周复发方面不劣于结肠镜输送。
  • 两组单次治疗后无复发率均为96.2%,差异0%(单侧95%CI -6.1%至无穷;P<.001)。
  • 胶囊组体验为「完全不难受」的比例66% vs 结肠镜组44%(差异22%[95%CI 3%-40%];P=.01)。

核心结论

  • 在复发性艰难梭菌感染成人中,口服胶囊粪菌移植在预防12周内复发方面不劣于结肠镜输送。
  • 作者认为口服胶囊治疗可能是治疗复发性艰难梭菌感染的有效方法。

研究设计与样本

  • 非劣效、开放标签、随机试验,在加拿大阿尔伯塔省的3个学术中心开展。
  • 2014年10月至2016年9月期间入组116例复发性艰难梭菌感染成人患者,随访至2016年12月。
  • 参与者按1:1比例随机分配至胶囊组或结肠镜组接受粪菌移植。
  • 非劣效界值为15%。

主要发现

  • 116例随机患者平均(标准差)年龄58(19)岁,女性79例(68%);105例(91%)完成试验,胶囊组57例,结肠镜组59例。
  • 符合方案分析中,单次治疗后预防复发性艰难梭菌感染在胶囊组(51/53)和结肠镜组(50/52)均达到96.2%(差异0%;单侧95%CI -6.1%至无穷;P<.001),满足非劣效标准。
  • 每组各有1例患者死于与粪菌移植无关的潜在心肺疾病。
  • 轻微不良事件发生率胶囊组为5.4%,结肠镜组为12.5%。
  • 两组生活质量改善无显著组间差异。

关键数值与推荐

  • 主要结局为粪菌移植后12周无复发性艰难梭菌感染的患者比例。
  • 次要结局包括严重和轻微不良事件、36项简短健康调查量表(0分为最差生活质量,100分为最佳生活质量)的生活质量变化、患者感受(1分为完全不难受,10分为极度难受)和满意度(1分为最好,10分为最差)。
  • 非劣效界值为15%。
  • 符合方案分析中单次治疗后无复发性艰难梭菌感染率胶囊组96.2%(51/53)vs 结肠镜组96.2%(50/52),差异0%(单侧95%CI -6.1%至无穷;P<.001)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为口服胶囊治疗可能是治疗复发性艰难梭菌感染的有效方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fecal microbiota transplantation (FMT) is effective in preventing recurrent Clostridium difficile infection (RCDI). However, it is not known whether clinical efficacy differs by route of delivery. OBJECTIVE: To determine whether FMT by oral capsule is noninferior to colonoscopy delivery in efficacy. DESIGN, SETTING, AND PARTICIPANTS: Noninferiority, unblinded, randomized trial conducted in 3 academic centers in Alberta, Canada. A total of 116 adult patients with RCDI were enrolled between October 2014 and September 2016, with follow-up to December 2016. The noninferiority margin was 15%. INTERVENTIONS: Participants were randomly assigned to FMT by capsule or by colonoscopy at a 1:1 ratio. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients without RCDI 12 weeks after FMT. Secondary outcomes included (1) serious and minor adverse events, (2) changes in quality of life by the 36-Item Short Form Survey on a scale of 0 (worst possible quality of life) to 100 (best quality of life), and (3) patient perception on a scale of 1 (not at all unpleasant) to 10 (extremely unpleasant) and satisfaction on a scale of 1 (best) to 10 (worst). RESULTS: Among 116 patients randomized (mean [SD] age, 58 [19] years; 79 women [68%]), 105 (91%) completed the trial, with 57 patients randomized to the capsule group and 59 to the colonoscopy group. In per-protocol analysis, prevention of RCDI after a single treatment was achieved in 96.2% in both the capsule group (51/53) and the colonoscopy group (50/52) (difference, 0%; 1-sided 95% CI, -6.1% to infinity; P < .001), meeting the criterion for noninferiority. One patient in each group died of underlying cardiopulmonary illness unrelated to FMT. Rates of minor adverse events were 5.4% for the capsule group vs 12.5% for the colonoscopy group. There was no significant between-group difference in improvement in quality of life. A significantly greater proportion of participants receiving capsules rated their experience as "not at all unpleasant" (66% vs 44%; difference, 22% [95% CI, 3%-40%]; P = .01). CONCLUSIONS AND RELEVANCE: Among adults with RCDI, FMT via oral capsules was not inferior to delivery by colonoscopy for preventing recurrent infection over 12 weeks. Treatment with oral capsules may be an effective approach to treating RCDI. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02254811.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kao D, Roach B, Silva M, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017. PMID: 29183074. doi:10.1001/jama.2017.17077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。